These findings suggest that a feedforward cycle may exist in the TME, whereby VV-αCEA TCE treatment induces IFNγ production, elevating CEA levels and sensitizing CEA-positive tumour cells to TCE therapy. This evidence concerns the gene CEACAM5 and neoplasm.